Sea You at Fetch Long Beach
News|Articles|November 18, 2026

Dechra buys stem cell developer Gallant, with first therapy expected as early as 2027

The acquisition brings Gallant’s experimental stem cell treatments for feline chronic gingivostomatitis and osteoarthritis in dogs and cats into Dechra’s portfolio.

Dechra has acquired Gallant Pet Inc (Gallant), an animal health biotechnology company developing off-the-shelf mesenchymal stromal cell (MSC) therapies for dogs and cats, Dechra announced November 17. Terms of the deal were not disclosed.1

The acquisition moves Dechra, which focuses on veterinary specialty care, into regenerative medicine. Dechra said the first product from Gallant’s pipeline is anticipated as early as 2027 but did not name it.1

“This acquisition is a strategic investment in expanding what’s possible in veterinary care,” Cathy Knupp, DVM, MS, chief scientific officer of Dechra, said in a news release announcing the acquisition.1

“Gallant was built on a bold idea that we could make regenerative medicine accessible for all pets in need,” added Linda Black, DVM, PhD, CEO of Gallant.1 "Dechra understood that vision from the start. We are thrilled to begin this new chapter as part of Dechra who shares our dedication to science and heart. I'm incredibly proud of the team that got us here, and excited to keep pioneering together."

Gallant will continue to operate as usual for its employees, customers, and vendors as of right now, Dechra said in an emailed statement to dvm360.

Lead feline therapy has cleared 2 FDA technical sections

Gallant has previously described sonruvetcel injectable suspension, an intravenous therapy for cats with refractory feline chronic gingivostomatitis (FCGS), as its first expected product.2

Sonruvetcel is an allogeneic therapy made from uterine-derived MSCs sourced from healthy, specific pathogen–free donor cats. The FDA Center for Veterinary Medicine (CVM) issued technical section complete letters for the product’s reasonable expectation of effectiveness in September 2025 and its target animal safety in November 2025, the latter confirming that Gallant’s data met a 365-day safety requirement.3

In a 90-day field study published in September 2025 in the Journal of Feline Medicine and Surgery, 46 cats with refractory FCGS received 2 IV doses of allogeneic uterine-derived MSCs 14 days apart. At day 90, 78.8% of cats evaluated (26 of 33) met the study’s success threshold on an owner-reported quality-of-life measure, and 45.5% (15 of 33) showed improvement in veterinarian-scored oral lesions.4

Gallant had targeted conditional approval of sonruvetcel for early 2026 and said in April that it expected the product to be approved later in the year.3,5

In its statement to dvm360, Dechra declined to say whether sonruvetcel is the product now expected in 2027 or where it stands with the FDA. The company said Gallant’s pipeline is designed to support therapies across multiple conditions and species, including FCGS.

“We’re not sharing further details about individual therapies or the conditions they address at this time,” the company told dvm360. “What we can say today is that we believe in this new platform and are excited about the science behind it. We look forward to sharing more as programs progress and information becomes appropriate to communicate.”

“Dechra's acquisition of Gallant is a strategic investment aligned with Dechra’s long-term strategy to serve unmet needs in specialty care. The acquisition strengthens Dechra's position in specialty care and marks its expansion into regenerative medicine, with an emerging platform that has the potential to expand treatments for complex conditions, address unmet needs and help shape the future of care,” Dechra told dvm360.

Gallant’s osteoarthritis programs for cats and dogs

In April, Gallant reported results from a randomized, masked, placebo-controlled pilot study of an IV MSC therapy in 35 cats with osteoarthritis. At 90 days, 76.2% of treated cats met the threshold for improvement on an owner-reported quality-of-life measure, compared with 36.4% of cats given placebo. The FDA-CVM granted the program eligibility for its expanded conditional approval pathway.5

In May, the company reported results from a randomized, blinded, placebo-controlled pilot study in 88 dogs with osteoarthritis. Dogs that received 2 IV injections 14 days apart showed statistically significant improvement vs placebo on owner-reported outcome measures at days 60 and 90, according to Gallant, which did not release effect sizes or confidence intervals. At the time, Gallant said it was targeting conditional approval for the canine program in 2028.5

Gallant’s pipeline also includes programs for feline chronic kidney disease and canine atopic dermatitis.5

Because the cells must be stored at −80 °C, Gallant signed an agreement in February with MWI Animal Health to build an ultra-low temperature cold chain for delivering the therapies to veterinary clinics.2

Dechra’s past acquisitions added antibody and insulin programs

In July 2024, Dechra acquired Invetx, a Boston-based developer of monoclonal antibody therapies for dogs and cats, in a transaction valued at up to $520 million.7 Later that month, Dechra bought Akston Biosciences’ long-acting insulin programs for dogs and cats with diabetes, including once-weekly candidates for each species.8

References

  1. Dechra acquires biotechnology company, Gallant Pet, Inc. News release. Dechra. November 17, 2026. Accessed November 17, 2026. https://prnmedia.prnewswire.com/news-releases/dechra-acquires-biotechnology-company-gallant-pet-inc-302942442.html
  2. Gallant announces first-of-its-kind partnership with MWI Animal Health to deliver anticipated FDA-conditionally approved stem cell therapy into veterinary clinics. News release. Gallant. February 27, 2026. Accessed November 17, 2026. https://www.prnewswire.com/news-releases/gallant-announces-first-of-its-kind-partnership-with-mwi-animal-health-to-deliver-anticipated-fda-conditionally-approved-stem-cell-therapy-into-veterinary-clinics-302699723.html
  3. McCafferty C. Gallant achieves drug approval milestone. dvm360. November 12, 2025. Accessed November 17, 2026. https://www.dvm360.com/view/gallant-achieves-drug-approval-milestone
  4. Williams VS, Schneider JL, Parrish RS, et al. Clinical field study evaluating the safety and efficacy of allogeneic uterine-derived mesenchymal stem cells for refractory feline chronic gingivostomatitis. J Feline Med Surg. 2025;27(11):1098612X251385852. doi:10.1177/1098612X251385852
  5. Bautista-Alejandre A. Ready-to-use feline OA stem cell therapy gains entry to FDA’s faster conditional approval pathway. dvm360. April 15, 2026. Accessed November 17, 2026. https://www.dvm360.com/view/ready-to-use-feline-oa-stem-cell-therapy-gains-entry-to-fda-s-faster-conditional-approval-pathway
  6. Pilot study supports IV MSC therapy for canine osteoarthritis. dvm360. May 7, 2026. Accessed November 17, 2026. https://www.dvm360.com/view/pilot-study-supports-iv-msc-therapy-for-canine-osteoarthritis
  7. Novo Holdings portfolio company Invetx to be acquired by Dechra Pharmaceuticals. News release. Novo Holdings. July 18, 2024. Accessed November 17, 2026. https://novoholdings.dk/news/novo-holdings-portfolio-company-invetx-to-be-acquired-by-dechra-pharmaceuticals
  8. Coppock K. Global veterinary pharmaceutical specialist acquires innovative insulin programs. dvm360. July 30, 2024. Accessed November 17, 2026. https://www.dvm360.com/view/global-veterinary-pharmaceutical-specialist-acquires-innovative-insulin-programs

Related to this article